Barclays
NVCT icon

Barclays’s Nuvectis Pharma NVCT Stock Holding History

Barclays’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1K Sell
3,121
-21,064
-87% -$180K ﹤0.01% 4537
2025
Q4 		$183K Buy
24,185
+5,760
+31% +$37.5K ﹤0.01% 4367
2025
Q3 		$111K Sell
18,425
-4,749
-20% -$32.6K ﹤0.01% 4581
2025
Q2 		$173K Buy
23,174
+22,015
+1,899% +$200K ﹤0.01% 4369
2025
Q1 		$11.3K Buy
1,159
+15
+1% +$108 ﹤0.01% 4859
2024
Q4 		$6.19K Hold
1,144
– – ﹤0.01% 5040
2024
Q3 		$7.2K Sell
1,144
-7,126
-86% -$46.9K ﹤0.01% 5003
2024
Q2 		$52.3K Sell
8,270
-2,023
-20% -$13.8K ﹤0.01% 4194
2024
Q1 		$84.4K Buy
10,293
+39
+0.4% +$332 ﹤0.01% 4494
2023
Q4 		$85.5K Buy
10,254
+8,865
+638% +$79.1K ﹤0.01% 4671
2023
Q3 		$17.9K Buy
1,389
+18
+1% +$261 ﹤0.01% 4202
2023
Q2 		$21.9K Buy
+1,371
New +$21.9K ﹤0.01% 4118

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays's NVCT Position: Q1 2026 in Review

Barclays reduced its Nuvectis Pharma (NVCT) stake by 87% in Q1 2026, selling an estimated $180K and leaving 3,121 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4537.

Barclays first reported a position in NVCT in Q2 2023 and has held it in 12 quarters since. The position peaked at $183K in Q4 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Barclays held 3,121 shares of Nuvectis Pharma worth $24.1K as of Q1 2026.
  • Barclays sold 21,064 Nuvectis Pharma shares in Q1 2026, an estimated $180K.
  • Nuvectis Pharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4537 holding.
  • Barclays first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 12 quarters since.
  • Barclays's Nuvectis Pharma position peaked at $183K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.